List of Excipients in Branded Drug USTEKINUMAB

Ustekinumab Excipient Strategy and Commercial Opportunities

Last updated: September 8, 2026

Ustekinumab is a mature monoclonal-antibody product with declining exclusivity and an expanding biosimilar market. The principal excipient opportunity is not a new active ingredient but a differentiated formulation and manufacturing package that improves aggregation control, subcutaneous delivery, container compatibility, cold-chain resilience, or device performance.

The commercial market is anchored by Stelara, marketed by Johnson & Johnson’s Janssen unit, and by ustekinumab biosimilars entering the United States and other major markets. Excipient suppliers, contract manufacturers, device companies, and biosimilar developers can compete through stability data, low-particle systems, high-concentration delivery, and integrated container-closure platforms.

What excipients are used in Stelara ustekinumab formulations?

Stelara uses a relatively simple excipient system based on histidine buffer, polysorbate 80, sucrose, and water for injection. The intravenous formulation also contains disodium EDTA.

Product presentation	Strength and route	Principal excipients
Stelara prefilled syringe or vial	45 mg/0.5 mL, subcutaneous	L-histidine, L-histidine monohydrochloride monohydrate, polysorbate 80, sucrose, water for injection
Stelara prefilled syringe or vial	90 mg/1.0 mL, subcutaneous	L-histidine, L-histidine monohydrochloride monohydrate, polysorbate 80, sucrose, water for injection
Stelara vial	130 mg/26 mL, intravenous	L-histidine, L-histidine monohydrochloride monohydrate, polysorbate 80, sucrose, disodium EDTA, water for injection

The subcutaneous product is supplied at approximately 90 mg/mL. That concentration creates formulation demands that are materially different from those of many lower-concentration antibody products. The formulation must control viscosity, aggregation, subvisible particles, oxidation, and adsorption while remaining compatible with a prefilled syringe or autoinjector.

Stelara’s label identifies sucrose as a stabilizing excipient, histidine as the buffering system, and polysorbate 80 as a surfactant. EDTA is included in the intravenous presentation but not in the listed subcutaneous formulation. [1]

What is the commercial role of each ustekinumab excipient?

Histidine buffer

Histidine controls formulation pH and helps preserve antibody structure during storage. Its commercial value lies in grade consistency, low bioburden, low endotoxin, and compatibility with long-term refrigerated storage.

Potential supplier differentiation includes:

• Pharmaceutical-grade histidine with tight impurity controls.
• Low-metal and low-peroxide specifications.
• Reliable global supply under biologics GMP systems.
• Documentation supporting comparability and regulatory filings.
• Manufacturing processes that reduce lot-to-lot variability.

Histidine is widely used in antibody formulations, so it is unlikely to provide meaningful product exclusivity by itself. Its value is more likely to arise from performance in a specific ustekinumab formulation and from supply reliability.

Polysorbate 80

Polysorbate 80 reduces interfacial stress and limits adsorption to glass, polymer, and silicone surfaces. It is also one of the most technically sensitive excipients in antibody products.

Hydrolysis and oxidation of polysorbate 80 can generate free fatty acids, peroxides, and particles. These degradation products can affect protein stability and may create visible or subvisible particulate risk. [2,3]

Commercial opportunities include:

• Low-peroxide polysorbate 80.
• Controlled fatty-acid composition.
• High-purity, low-particle grades.
• Stabilized or hydrolysis-resistant surfactant systems.
• Analytical packages linking surfactant degradation to antibody quality attributes.
• Alternatives such as polysorbate 20, poloxamers, or newer recombinant-protein-compatible surfactants.

A switch from polysorbate 80 to another surfactant would require a full comparability package. The key risks would include altered aggregation, immunogenicity, extractables, leachables, adsorption, and container-closure interaction.

Sucrose

Sucrose acts as a stabilizer and cryo- or lyoprotectant. In liquid subcutaneous products, it helps maintain the folded antibody structure during refrigerated storage and during brief temperature excursions.

Sucrose is a commodity excipient. Commercial value depends on:

• Pharmaceutical-grade purity.
• Low endotoxin and low bioburden.
• Consistent moisture and degradation profiles.
• Compatibility with high-concentration liquid antibodies.
• Support for freeze-thaw and agitation studies.

The most attractive opportunity is not a new sucrose patent. It is a formulation package showing that sucrose supports longer shelf life, lower aggregation, or improved shipping robustness.

Disodium EDTA

EDTA is used in the intravenous formulation and can chelate trace metals that catalyze oxidation. Its absence from the listed subcutaneous formulation indicates that the subcutaneous product uses a different impurity-control strategy or does not require the same level of metal-ion management.

EDTA can reduce oxidative stress, but it may interact with manufacturing equipment, container materials, and analytical assays. Its inclusion in a subcutaneous product would require evidence that it improves stability without creating tolerability or compatibility problems.

Water for injection

Water for injection is the continuous phase of the product. It is generally not a source of formulation differentiation, but water quality, production controls, and endotoxin management remain critical to injectable biologics manufacturing.

What formulation strategies are available for ustekinumab biosimilars?

Biosimilar developers have several formulation pathways, but each has different regulatory and commercial implications.

Strategy	Commercial advantage	Principal risk
Match the reference formulation	Simplifies analytical and regulatory comparability	Limited differentiation and continued dependence on legacy excipients
Use the same excipients with optimized concentrations	Preserves familiarity while improving stability or injection performance	May require extensive comparative data
Replace polysorbate 80	Could reduce particles, oxidation, or surfactant degradation	High comparability, immunogenicity, and regulatory burden
Increase protein concentration	May reduce injection volume	Higher viscosity, aggregation, and device-force risk
Develop a low-volume autoinjector	Improves patient convenience and differentiation	Device combination-product requirements
Develop a room-temperature-stable presentation	Reduces cold-chain cost	Requires substantial real-time and accelerated stability evidence
Develop a lyophilized product	Potentially improves stability	Adds reconstitution burden and manufacturing cost
Optimize the container closure	Reduces adsorption, silicone interaction, and extractables	May require new compatibility and particulate studies

The lowest-risk path is generally a reference-like histidine-polysorbate-sucrose formulation in a comparable concentration and presentation. This approach supports biosimilar comparability and reduces clinical and regulatory complexity.

The highest-value path is a differentiated presentation with a clear patient or supply-chain benefit, such as a lower-volume autoinjector or a formulation with improved temperature excursion tolerance. These benefits can support commercial positioning even when the underlying antibody is biosimilar.

What formulation patents protect ustekinumab products?

Ustekinumab patent protection is primarily associated with the antibody, its biological targets, manufacturing processes, and therapeutic uses. Excipient protection is narrower and usually depends on a claimed combination of:

• Ustekinumab or a defined antibody sequence.
• A specific buffer system.
• A specified surfactant and stabilizer.
• Defined pH and concentration ranges.
• Aggregation, particle, or potency limits.
• A particular container or delivery device.
• A storage condition or shelf-life result.

A broad claim to histidine, polysorbate 80, and sucrose would face substantial validity and obviousness pressure because these excipients are established in monoclonal-antibody formulations. Stronger claims would link the composition to a measurable technical result, such as reduced high-molecular-weight species, reduced particles after agitation, or improved stability at a defined concentration.

Orange Book status

Stelara is a biologic, not a small-molecule drug listed in the FDA Orange Book. Its patent and regulatory framework is therefore different from that of an Abbreviated New Drug Application product.

The key U.S. framework is the Biologics Price Competition and Innovation Act, which provides for biosimilar applications under section 351(k) of the Public Health Service Act. Patent disputes are handled through the BPCIA patent-exchange process and federal litigation rather than through the standard Orange Book Paragraph IV mechanism used for small molecules. [4]

As a result, “Orange Book-listed ustekinumab patents” is not the correct search category. Relevant rights should be reviewed through biologic patent families, FDA Purple Book records, USPTO databases, court dockets, and BPCIA settlement disclosures.

When does ustekinumab lose exclusivity?

The commercial exclusivity analysis has several layers:

Exclusivity category	Stelara position
FDA biologic exclusivity	The 12-year reference-product exclusivity period has expired
Core composition patents	Principal early patent protection has expired or reached the end of its effective term in major markets
Formulation and process patents	Scope and enforceability depend on jurisdiction and individual patent family
Method-of-use patents	May remain relevant for specific indications or dosing regimens
Biosimilar market entry	Began or is scheduled through negotiated settlements and regulatory approvals
Market exclusivity after entry	No small-molecule-style automatic generic substitution; biosimilar interchangeability depends on FDA designation

The commercial transition accelerated after Johnson & Johnson reached settlement agreements with multiple biosimilar developers. Publicly disclosed agreements established staggered U.S. and European entry dates rather than allowing unrestricted immediate competition. [5]

Which companies are challenging Stelara?

The ustekinumab competitive field includes biosimilar developers and large pharmaceutical companies with antibody manufacturing capabilities.

Notable participants include:

• Amgen, with Wezlana, also known as ustekinumab-auub.
• Celltrion.
• Samsung Bioepis.
• Biocon Biologics.
• Fresenius Kabi.
• Teva Pharmaceutical Industries.
• Alvotech and commercial partners.
• Other regional developers pursuing approval outside the United States.

Amgen’s Wezlana received FDA approval in 2024 for reference-product indications supported by the applicable biosimilar pathway. The product is available in subcutaneous and intravenous presentations corresponding to major Stelara use cases. [6]

The commercial contest is likely to focus on supply reliability, contracting, interchangeability, injection devices, payer access, and manufacturing cost rather than on major differences in the antibody molecule.

What is the FDA regulatory status of ustekinumab biosimilars?

Ustekinumab biosimilars are regulated under the 351(k) pathway. FDA approval requires a demonstration that the product is highly similar to the reference product, with no clinically meaningful differences in safety, purity, and potency. [7]

Excipient changes are permissible, but they increase the analytical burden. A biosimilar developer must evaluate:

• Primary and higher-order structure.
• Charge variants and glycan profile.
• Aggregation and fragmentation.
• Potency and binding activity.
• Host-cell proteins and residual process impurities.
• Particulate matter.
• Stability under intended storage and stress conditions.
• Immunogenicity risk.
• Container-closure compatibility.

The FDA may accept a biosimilar with a different formulation if the totality of evidence supports the required similarity standard. A reference-matched excipient system remains commercially attractive because it minimizes avoidable comparability questions.

How strong is the ustekinumab excipient patent estate?

The excipient patent estate is likely weaker than the antibody composition and therapeutic-use estate. Its strength depends on claim construction, priority dates, prosecution history, written-description support, and evidence that the formulation delivers an unexpected technical result.

Stronger claim characteristics

• Narrowly defined formulation ranges.
• Specific concentration and pH combinations.
• Data showing reduced aggregation or particles.
• Claims tied to a particular delivery device.
• Defined stability after agitation, freezing, or temperature excursion.
• Claims supported by comparative examples against conventional formulations.

Weaker claim characteristics

• Generic use of sucrose as a stabilizer.
• Generic use of histidine buffer.
• Generic use of polysorbate 80.
• Broad antibody formulations without comparative data.
• Claims covering standard excipient combinations known in antibody development.

For biosimilar developers, the main freedom-to-operate risk is often not the excipient itself. It is the combination of formulation, concentration, device, manufacturing process, and method of use.

What manufacturing and IP barriers affect ustekinumab commercialization?

Ustekinumab manufacturing requires a high-performing mammalian-cell culture and purification process. The key technical barriers include:

• Stable cell-line productivity.
• Removal of host-cell proteins and DNA.
• Control of aggregates and charge variants.
• Viral clearance validation.
• Consistent glycosylation.
• Low-particle formulation manufacture.
• Aseptic filling of high-value protein drug product.
• Supply of pharmaceutical-grade surfactants and buffers.
• Compatibility with prefilled syringes and autoinjectors.

Excipient changes can alter downstream manufacturing behavior. Polysorbate concentration can affect filtration and particle profiles. Buffer selection can affect chromatography and hold stability. Higher protein concentration can increase filtration pressure, viscosity, and filling-force requirements.

A contract development and manufacturing organization can create commercial value by offering an integrated ustekinumab platform covering formulation screening, device compatibility, analytical comparability, and fill-finish operations.

What commercial opportunities exist in ustekinumab excipients?

Excipient suppliers

The most defensible opportunities are premium grades of polysorbate 80, oxidation-controlled surfactants, low-particle excipients, and technical support packages. Suppliers that provide validated impurity analytics can command greater value than commodity suppliers.

Biosimilar developers

Biosimilar companies can use excipient strategy to reduce manufacturing cost or improve product usability. A reference-like formulation is the most efficient route to market, while a differentiated formulation can support contracting and physician adoption.

Device companies

Ustekinumab’s subcutaneous dosing supports opportunities for prefilled syringes, autoinjectors, and low-force delivery systems. Device performance must account for viscosity, injection volume, needle gauge, storage temperature, and user handling.

Contract manufacturers

CDMOs can package formulation, analytical characterization, sterile filling, and device assembly into one program. This is particularly valuable for smaller biosimilar developers that lack internal biologics infrastructure.

Cold-chain and logistics providers

A formulation with improved temperature-excursion tolerance could reduce spoilage and distribution cost. Such a claim would require robust real-time and accelerated stability data and would not be established by short-term stress testing alone.

How does ustekinumab compare with other antibody products?

Ustekinumab is commercially attractive because it combines a large established market with a mature formulation platform and multiple biosimilar entrants.

Attribute	Ustekinumab	Typical antibody biosimilar opportunity
Reference product	Stelara	Varies
Main formulation challenge	High-concentration subcutaneous delivery	Depends on molecule and route
Core excipients	Histidine, polysorbate 80, sucrose	Often similar platform excipients
IV presentation	Yes	Product-specific
Device opportunity	High	Depends on dose volume and viscosity
Excipient differentiation	Moderate	Highest where reference formulation has stability or device limitations
Legal risk	Biologic patent and BPCIA framework	Product-specific
Commercial pressure	High because of multiple entrants	Varies by market and entry timing

Compared with many older monoclonal antibodies, ustekinumab has a stronger opportunity for device and formulation differentiation because the commercial product includes both intravenous induction and subcutaneous maintenance use.

Key Takeaways

• Stelara uses histidine, polysorbate 80, sucrose, and water for injection in its subcutaneous presentation; the intravenous product also includes disodium EDTA.
• Polysorbate 80 quality and degradation control are the most commercially significant excipient issues.
• A reference-matched formulation is the lowest-risk biosimilar strategy.
• Higher-value opportunities involve low-particle formulations, improved temperature tolerance, optimized prefilled syringes, and autoinjectors.
• Ustekinumab is a biologic, so Orange Book Paragraph IV analysis is not the correct framework.
• The relevant legal framework is the BPCIA, supported by Purple Book, USPTO, patent litigation, and settlement analysis.
• Excipient claims are strongest when tied to defined stability or delivery results rather than generic use of established ingredients.
• The competitive market includes Amgen, Celltrion, Samsung Bioepis, Biocon Biologics, Fresenius Kabi, Teva, Alvotech, and regional developers.
• The largest commercial risk is price erosion from multiple biosimilar entrants. The strongest differentiation levers are supply reliability, device usability, interchangeability, and manufacturing cost.

FAQs About Ustekinumab Excipient Commercialization

Can polysorbate 80 be replaced in an ustekinumab biosimilar?

Yes. A developer can evaluate polysorbate 20, poloxamers, or other surfactants, but the change requires extensive analytical, stability, immunogenicity, and container-compatibility evidence.

Is a sucrose-histidine formulation patentable for ustekinumab?

Potentially, but generic use of sucrose and histidine is unlikely to provide strong protection. Patent strength improves when the claims define concentration ranges and demonstrate unexpected stability or particle-control results.

Does ustekinumab require a preservative?

The commercial injectable presentations are supplied as single-dose products and do not rely on a conventional antimicrobial preservative system.

Can an ustekinumab biosimilar use a different injection device?

Yes. A different prefilled syringe or autoinjector may be used if the product-device combination meets applicable FDA requirements and the formulation performs consistently in that device.

What is the highest-value excipient opportunity for ustekinumab?

A controlled-quality polysorbate 80 or alternative surfactant platform that reduces oxidation, particles, and aggregation in a high-concentration subcutaneous formulation has the strongest technical and commercial potential.

References

1. Janssen Biotech, Inc. (2024). STELARA (ustekinumab) injection, for subcutaneous or intravenous use: Prescribing information. U.S. Food and Drug Administration.

2. Kerwin, B. A. (2008). Polysorbate 20 and 80 used in the formulation of protein biotherapeutics: Structure and degradation pathways. Journal of Pharmaceutical Sciences, 97(8), 2924-2935.

3. Kishore, R. S. K., Pappenberger, A., Dauphin, I. B., Ross, A., nationals? & others. (2011). Degradation of polysorbates 20 and 80: Studies on thermal autoxidation and hydrolysis. Journal of Pharmaceutical Sciences, 100(10), 4119-4131.

4. U.S. Food and Drug Administration. (2024). Biologics Price Competition and Innovation Act of 2009. FDA.

5. Johnson & Johnson. (2024). Annual report and disclosures concerning STELARA biosimilar settlements. Johnson & Johnson.

6. U.S. Food and Drug Administration. (2024). WEZLANA (ustekinumab-auub) prescribing information. FDA.

7. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. FDA.